Additional file 2: of Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
Year: 2018
Type: article
Abstract: Figure S1. (A) Lollipop plot shows the distribution of POLE mutations in UCEC, LUAD and LUSC cancers. (B) TMB cannot stratify LUAD patients. Figure S2. PD-L1 expression cannot stratify (A) LUAD or (D) LUSC patients without POLE mutations. (B) POLE mutation is associated with higher mutation rates. (C) The combination of POLE mutations and PD-L1 expression is not predictive to LUSC patient outcomes. (E) POLE-mutant patients have slighter higher percentages of TIL. (F) Mut-High group of patients have lower TIL but better survivals. Figure S3. There were 96 genes that were identified to be significantly mutated in Mut-High group but not Mut-Low group with P < 0.05 (Fisher’s exact test). Figure S4. (A) Comparisons of immune-related gene expression in Mut-High and Mut-Low groups. (B) GSEA pathway enrichment and (C) GO function enrichment of the differentially expressed genes in Mut-High and Mut-Low groups. (DOCX 16386 kb)
Source: Figshare
Authors: Liu, Liang, Ruiz, Jimmy, O’Neill, Stacey, Grant, Stefan, Petty, W., Yang, Meng, Chen, Kexin, Topaloglu, Umit, Pasche, Boris, Zhang, Wei
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2998902713